EMMPRIN's new clothes

EMMPRIN dropped off the drug discovery map in 2003 when Abgenix Inc.'s antibody against the target failed in a Phase II/III trial to treat graft-versus-host disease. Now, findings from Canadian researchers suggest it might be worthwhile to revisit this extracellular matrix metalloproteinase inducer in multiple sclerosis.1 The researchers

have antibodies against the target and are seeking an industry


EMMPRIN (basigin Ok blood group; BSG; CD147) is a master regulator of matrix metalloproteinases (MMPs) and plays

Read the full 757 word article

How to gain access

Continue reading with a
two-week free trial.